ABSTRACT
Background Fluoroquinolone use for urinary tract infections has been steadily declining. Gut microbiota is the main reservoir for uropathogenic Escherichia coli but whether the carriage of fluoroquinolone-resistant E. coli has been changing is unknown.
Methods We determined the frequency of isolation and other characteristics of E. coli nonsuceptible to fluoroquinolones (at ≥0.5 mg/L of ciprofloxacin) in 515 and 1605 E. coli-positive fecal samples collected in 2015 and 2021, respectively, from non-antibiotic-taking women of age 50+ receiving care in the Seattle area Kaiser Permanente Washington healthcare system.
Results Between 2015 and 2021 the prescription of fluoroquinolones dropped nearly three-fold in the study population. During the same period, the rates of gut carriage of fluoroquinolone-resistant E. coli increased from 14.4 % to 19.9% (P=.005), driven by a significant increase of isolates from the recently emerged, pandemic multi-drug resistant clonal group ST1193 (1.7% to 4.3%; P=.007) and those with an incomplete set of or no fluoroquinolone-resistance determining mutations (2.3% to 7.5%; P<.001). While prevalence of the resistance-associated mobile genes among the isolates dropped from 64.1% to 32.6% (P<.001), co-resistance to third generation cephalosporins has increased 21.5% to 33.1%, P=.044).
Conclusion Despite reduction in fluoroquinolone prescriptions, gut carriage of fluoroquinolone-resistant uropathogenic E. coli increased with a rise of previously sporadic lineages and co-resistance to third generation cephalosporins. Thus, to reduce the rates of antibiotic resistant urinary tract infections, greater focus should be on controlling the gut carriage of resistant bacteria.
Short summary While prescription of fluoroquinolones dropped between 2015 and 2021, there was an increase in gut carriage of fluoroquinolone-resistant Escherichia coli among women of age 50+. Also, a rise of new resistant lineages and co-resistance to 3rd generation cephalosporins occurred.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study on collection and analysis of fecal and urine samples from women enrollees in Kaiser Permanente Washington was approved by the Kaiser Permanente Washington (KPWA) Research Institute Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are either contained in the manuscript or are available upon request to the authors.
